Daiichi Sankyo Condemns Falsely-represented Product
Product sold online in Malaysia and Indonesia infringes on the company’s trademark.
Daiichi Sankyo warned that a product being sold online to consumers in Malaysia and Indonesia is illegally using Daiichi Sankyo’s name, logo, and registered trademark and is not manufactured or sold by any Daiichi Sankyo Group companies or subcontractors. The package of the falsely represented product, Glutax 4G Premium, is similar to one of Daiichi Sankyo’s Asian prescription-drug products, the company reported. Daiichi Sankyo placed advertisements in Malaysian and Indonesian consumer publications to warn consumers of the deceit.
Daiichi Sankyo said that the advertisements were published because protecting consumers is its highest priority. The advertisements were published in Malaysian newspapers at the end of January and in February magazine issues, as well as in Indonesian newspapers at the end of February and in March or April magazine issues. The company is preparing to take legal action and is consulting with Malaysian authorities, the company announced in a
March 5, 2013 press release
.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
